BioN­Tech inks part­ner­ship with UK to speed up re­cruit­ment of mR­NA can­cer tri­als

BioN­Tech wants to roll out per­son­al­ized can­cer ther­a­pies quick­er, and it’s en­list­ing the UK gov­ern­ment for help.

The Ger­man biotech, best known for its work with Pfiz­er on the US’ first ap­proved Covid vac­cine, an­nounced Fri­day that it has inked a “mem­o­ran­dum of un­der­stand­ing” with the UK gov­ern­ment to ac­cel­er­ate the re­cruit­ment of tri­als for mR­NA im­munother­a­pies in a va­ri­ety of can­cers. The goal is to treat as many as 10,000 can­cer pa­tients by the end of 2030, ei­ther in clin­i­cal tri­als or with au­tho­rized treat­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER